In Vivo Pharmacokinetic Evaluation of IBD Drugs

Pharmacokinetics (PK) is the study of the kinetics of absorption, distribution, metabolism and excretion (ADME) of drugs and their corresponding pharmacologic, therapeutic, or toxic responses in animals. Appropriate pharmacokinetic profiling is a critical step in the drug development process. During preclinical IBD drug development, pharmacokinetic parameters can be first predicted using in silico models and then determined using both in vitro and in vivo models. Despite the value of both in silico and in vitro models, in vivo studies in different animal species are required before entering clinical phases.

Our In Vivo Pharmacokinetics Services

At Ace Therapeutics, we offer services to support your non-GLP in vivo pharmacokinetic studies of IBD drugs in preclinical species.  From compound ranking to drug-drug interaction evaluation, we offer a full range of customized PK services. Using state-of-the-art analytics (HPLC-MS) and specialized models, we help clients characterize the pharmacokinetic profile of IBD drugs and inform the efficacy of an IBD drug by validating that it reaches the required concentration levels in plasma and tissues.
Our comprehensive portfolio of in vivo PK research services.

• Rank-ordering compounds
• Formulation screening
• Standard and special PK
• Excretion balance
• Tissue distribution (non-radioactive and radioactive)
• Metabolite quantification
• Drug-drug interactions
• Pharmacodynamic and pharmacokinetic/pharmacodynamics modeling

PK Administration Routes and Collection

Our routes of administration and sampling protocols are specifically designed to meet our clients' needs and experimental objectives. Our extensive knowledge and expertise in in vivo PK studies contribute to the successful development of IBD drugs.

• Various animal species: Mice, rats, rabbits, guinea pigs, dogs, non-human primates.
• Multiple routes of administration: Intravenous, oral, intraperitoneal, intramuscular, subcutaneous, intracolonic.
• Simultaneous cassette PK screening of up to 5 compounds.
• Cassette PK screening of up to 5 compounds simultaneously.
• Different sampling routes: Jugular vein cannulation, cardiac puncture, tail vein microsampling, retro-orbital.
• Sampling time: Can be set to 24 hours or more depending on compound characteristics and program requirements.
• Different matrices: Blood, plasma, colon tissue, bile, urine, and feces.
• Collecting colon tissue and blood to assess the colon tissue/plasma drug concentration ratio.
• Calculation of PK parameters: Clearance, volume of distribution, AUC, half-life (T_1/2), C_max, T_max and bioavailability.

Why Choose Us

• We can conduct studies from discovery through development, using species ranging from rodents to non-rodents, multiple routes of administration, and multiple sample collections to meet the diverse needs of our clients.
• We investigate a variety of doses, routes of administration, and subsequent monitoring of drug concentrations and levels in biological systems.
• Our systematic approach and extensive capabilities combine technology with deep scientific understanding to ensure that the pharmacokinetic profile of your IBD drug is thoroughly explored and understood.
• By carefully analyzing and interpreting pharmacokinetic data, we ensure that each project is conducted with the highest level of accuracy and scientific rigor, ultimately contributing to the development of safe and effective treatments for IBD.

Ace Therapeutics is committed to providing our clients with a comprehensive in vivo pharmacokinetic service platform, building the appropriate experimental system and pharmacokinetic screening strategy around clients' needs, including data interpretation and data application, to meet the in vivo pharmacokinetic evaluation needs of their IBD drugs. If you are interested in our services, please do not hesitate to contact us.